Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types.
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Other seizure types (off-label or per local protocol).
## Adult Dosing
**Lennox-Gastaut Syndrome (LGS):**
* **Starting dose:** 5 mg twice daily.
* **Titration:** Increase by 5 mg to 10 mg every week as tolerated, up to a maximum of 20 mg twice daily.
* **Maintenance dose:** Typically 10 mg to 20 mg twice daily.
**Other Seizure Types (if applicable per local protocol):**
* Dosing varies based on indication and patient response. Consult specific guidelines or local protocols.
## Pediatric Dosing (2 years and older)
**Lennox-Gastaut Syndrome (LGS):**
* **Starting dose:** 0.5 mg/kg/day divided into two doses.
* **Titration:** Increase by 0.5 mg/kg/day every week as tolerated, divided into two doses, up to a maximum daily dose of 1 mg/kg/day, not to exceed 20 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Lower doses may be necessary.
* **Renal Impairment:** Use with caution. Lower doses may be necessary.
* **Concomitant Medications:** Dose adjustments may be needed, especially with CYP3A4 inhibitors or inducers, and other CNS depressants.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
**Common:** Drowsiness, somnolence, drooling, constipation, decreased appetite, aggression, irritability, difficulty with coordination, behavioral problems.
**Serious:** Suicidal behavior/ideation, respiratory depression, severe skin reactions (e.g., Stevens-Johnson syndrome), withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other benzodiazepines):** Additive CNS depression, increased risk of sedation, respiratory depression, coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, grapefruit juice):** May increase clobazam levels.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam levels.
* **Stimulants (e.g., methylphenidate):** May blunt the effect of stimulants.
## Monitoring
* **Seizure frequency and type:** Monitor for efficacy and breakthrough seizures.
* **Behavioral changes:** Especially in children, monitor for aggression, irritability, and suicidal ideation.
* **Sedation and CNS depression:** Assess level of alertness and coordination.
* **Signs of withdrawal:** If discontinuing, monitor for symptoms like insomnia, anxiety, tremor, and seizures.
* **Liver and renal function:** Periodically, especially in patients with pre-existing impairment.
## Clinical Pearls
* Clobazam should be initiated at a low dose and titrated slowly to minimize adverse effects, particularly sedation and behavioral changes.
* Abrupt discontinuation can lead to withdrawal symptoms. Taper the dose gradually.
* Clobazam is a Schedule IV controlled substance.
* Due to the potential for serious skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and local protocols for complete details.
